Effects of Low- and High-Dose Chemotherapy Agents on Thrombogenic Properties of Extracellular Vesicles Derived from Breast Cancer Cell Lines

Abstract

These findings suggest that thrombogenic properties of BC-derived EVs may depend on the type and dose of the applied chemotherapy agent and may also be affected by the cell metastatic nature.

Extracellular Vesicle Proteome of Breast Cancer Patients with and Without Cognitive Impairment Following Anthracycline-based Chemotherapy: An Exploratory Study

“…It was also reported that miR-181c is related to the brain metastasis of breast cancer patients and their release through EVs promotes the destruction of the BBB through the abnormal localization of actin. Interestingly, chemotherapy could alter the properties of EVs from plasma of breast cancer patient 15 and was found to have thrombogenic effects on endothelial cells, 16 which might be 2 Biomarker Insights indicative for chemotherapy-related thrombogenicity or vascular damage. Indeed, cancer and chemotherapy can alter EVs composition and release, shedding light on the pathogenesis of cancer-and therapy-related adverse events.…”

Extracellular Vesicles Reflect the Efficacy of Wheatgrass Juice Supplement in Colon Cancer Patients During Adjuvant Chemotherapy

“…Furthermore, a significant increase in the EV TF/TFPI ratio was found after the first 24 h of doxorubicin treatment. In addition, EVs derived from MDA-MB-231 cells stimulated with high-dose doxorubicin demonstrated significantly increased procoagulant activity compared to EVs isolated from MDA-MB-231 cells pre-exposed to serum-free medium (19).…”

“…Pro-coagulant activity was evaluated using the Factor X activated (FXa) assay as previously described (19). Briefly, 25 µl of EV pellet isolated from 1 ml PPP, were mixed in 50 µl of Ca +2 Tris buffer (25 mM, pH 8) with 25 µl FVIIa (Novoseven, Novo Nordisk, Copenhagen, Denmark) and 1 ng/ml FX (American Diagnostica), and incubated for 15 min at 37 • C. Then, chromogenic substrate was added (2.5 mM Spectrozyme FXa, American Diagnostica, Greenwich, CT, United States) for an additional incubation time of 30 min at 37 • C. Samples' absorbance at 405 nm was then measured with a plate reader.…”

Thrombosis and Haemostasis 2019 Editor's Choice Papers

“…Thromboembolic complications of cancer is well recognised in children and adults reflected by the wealth of recent publications in Thrombosis & Haemostasis. [38][39][40][41][42][43][44][45] Because the risk of bleeding might be more important in children than in the general population, it is crucial to assess safety and efficacy of thromboprophylaxis specifically in children. In this context, the efforts from Pelland-Marcotte et al 46 to systematically review the effectiveness and safety of primary thromboprophylaxis in children with cancer in a network meta-analysis study were most welcome.…”